title: Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet.
abstract: Nonalcoholic steatohepatitis (NASH) comprises dysregulation of lipid metabolism and inflammation. Identification of the various genetic and environmental susceptibility factors for NASH may provide novel treatments to limit inflammation and fibrosis in patients. This study utilized a mouse model of hypercholesterolemia, low-density lipoprotein receptor knockout (LDLr(-/-)) mice fed a high-fat diet for 5 months, to test the hypothesis that farnesoid X receptor (FXR) deficiency contributed to NASH development. Either the high-fat diet or FXR deficiency increased serum alanine aminotransferase activity, whereas only FXR deficiency increased bile acid and alkaline phosphatase levels. FXR deficiency and high-fat feeding increased serum cholesterol and triglycerides. Although high fat led to macrosteatosis and hepatocyte ballooning in livers of mice regardless of genotype, no inflammatory infiltrate was observed in the livers of LDLr(-/-) mice. In contrast, in the livers of LDLr(-/-)/FXR(-/-) mice, foci of inflammatory cells were observed occasionally when fed the control diet and were greatly increased when fed the high-fat diet. Consistent with enhanced inflammatory cells, hepatic levels of tumor necrosis factor alpha and intercellular adhesion molecule-1 mRNA were increased by the high-fat diet in LDLr(-/-)/FXR(-/-) mice. In agreement with elevated levels of procollagen 1 alpha 1 and TGF-beta mRNA, type 1 collagen protein levels were increased in livers of LDLr(-/-)/FXR(-/-) mice fed a high-fat diet. In conclusion, FXR deficiency induces pathologic manifestations required for NASH diagnosis in a mouse model of hypercholesterolemia, including macrosteatosis, hepatocyte ballooning, and inflammation, which suggest a combination of FXR deficiency and high-fat diet is a risk factor for NASH development, and activation of FXR may be a therapeutic intervention in the treatment of NASH.
authors.affiliation: Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center. 3901 Rainbow Blvd., Kansas City, KS 66160, USA.
authors.forename: Bo
authors.initials: B
authors.lastname: Kong
authors.forename: James P
authors.initials: JP
authors.lastname: Luyendyk
authors.forename: Ossama
authors.initials: O
authors.lastname: Tawfik
authors.forename: Grace L
authors.initials: GL
authors.lastname: Guo
mesh_terms: D000821:Animal Feed; D000818:Animals; D003433:Crosses, Genetic; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000172:deficiency*; D004041:Dietary Fats; D005234:Fatty Liver / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D005838:Genotype; D007249:Inflammation / Q000503:physiopathology; D008055:Lipids / Q000502:physiology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D016133:Polymerase Chain Reaction; D018160:Receptors, Cytoplasmic and Nuclear / Q000172:deficiency*; D011973:Receptors, LDL / Q000172:deficiency* / Q000235:genetics; D014157:Transcription Factors / Q000172:deficiency*; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D017931:DNA Primers; D004268:DNA-Binding Proteins; D004041:Dietary Fats; D008055:Lipids; D018160:Receptors, Cytoplasmic and Nuclear; D011973:Receptors, LDL; D014157:Transcription Factors; D000099150:Receptor, Farnesoid X-Activated